OpGen, Qiagen to ad­vance rapid AMR di­ag­nos­tics

BioSpectrum (Asia) - - WORLD NEWS -

OpGen, Inc. has an­nounced a col­lab­o­ra­tion with QIAGEN N.V. to ad­vance rapid di­ag­nos­tics for an­timi­cro­bial re­sis­tance (AMR). Strength­en­ing OpGen’s en­try into the United States mar­ket, the com­pa­nies have en­tered into an agree­ment to com­mer­cial­ize a new so­lu­tion for the de­tec­tion of mul­tidrug re­sis­tant bac­te­rial pathogens based on QIAGEN’s EZ1 Ad­vanced XL au­to­mated nu­cleic acid pu­rifi­ca­tion in­stru­men­ta­tion (EZ1) and kits for the United States. The EZ1 will be uti­lized in the test work­flow for the Acuitas AMR Gene Panel u5.47 prod­ucts. The AMR Gene Panel fam­ily of rapid di­ag­nos­tics tests has been de­signed to de­tect and iden­tify mul­tidru­gre­sis­tant bac­te­rial pathogens in urine and bac­te­rial iso­lates in ap­prox­i­mately two hours. The test was de­vel­oped for use with the Acuitas Light­house Soft­ware for pre­dict­ing an­tibi­otic re­sis­tance and high­res­o­lu­tion pathogen track­ing. The AMR Gene Panel u5.47 and the Acuitas Light­house Soft­ware are cur­rently avail­able for Re­search Use Only (RUO). Un­der the terms of the agree­ment, OpGen will pur­chase EZ1 in­stru­ments and reagent kits from QIAGEN and sell or place them with cus­tomers in the United States for use with the Acuitas AMR Gene Panel. The EZ1 is a Class I Med­i­cal De­vice listed with the Food and Drug Ad­min­is­tra­tion (FDA) that pro­vides full au­toma­tion with sam­ple prepa­ra­tion through­put of up to 14 sam­ples per one-hour run.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.